VIA
TXG icon

Vident Investment Advisory’s 10x Genomics TXG Stock Holding History

Vident Investment Advisory’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,618
Closed -$370K – 988
2023
Q2 		$370K Buy
6,618
+384
+6% +$20.8K 0.01% 794
2023
Q1 		$348K Buy
+6,234
New +$291K 0.01% 900
2022
Q1 		– Sell
-12,147
Closed -$1.81M – 1341
2021
Q4 		$1.81M Buy
12,147
+9
+0.1% +$1.38K 0.05% 494
2021
Q3 		$1.77M Sell
12,138
-844
-7% -$145K 0.05% 487
2021
Q2 		$2.54M Buy
12,982
+15
+0.1% +$2.71K 0.08% 310
2021
Q1 		$2.35M Buy
12,967
+7,086
+120% +$1.22M 0.08% 298
2020
Q4 		$833K Buy
+5,881
New +$853K 0.03% 589

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vident Investment Advisory's TXG Position: Q3 2023 in Review

Vident Investment Advisory sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 6,618 shares — an estimated $370K sold.

Vident Investment Advisory first reported a position in TXG in Q4 2020 and held it in 7 quarters. The position peaked at $2.54M in Q2 2021. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

  • Vident Investment Advisory reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 6,618 10x Genomics shares in Q3 2023, an estimated $370K.
  • Vident Investment Advisory first reported a position in 10x Genomics in Q4 2020 and held it in 7 quarters.
  • Vident Investment Advisory's 10x Genomics position peaked at $2.54M in Q2 2021.
  • 256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.